Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells

Biochemical and Biophysical Research Communications

Volumn 273, Issue 2, 2000, Pages 485-491

  Bamba, Hiromi ^a   Ota, Shinichi ^b   Kato, Akira ^a   Kawamoto, Chiaki ^a   Fujiwara, Kenji ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Colon carcinogenesis; Macrophage; Peroxisome proliferator activated receptor ; Prostaglandin; Vascular endothelial growth factor

Indexed keywords

CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROSTAGLANDIN; PROSTAGLANDIN E; PROSTAGLANDIN E1; PROSTAGLANDIN RECEPTOR; VASCULOTROPIN;

ARTICLE; CELL DIFFERENTIATION; CELL STRAIN U937; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL;

EID: 0033880663     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2969     Document Type: Article

References (41)

1. Shiff S. J., Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: evolving concepts of their chemopreventive actions. Gastroenterology. 113:1997;1992-1998.
2. Smith W. L., Garavito R. M., DeWitt D. L. Prostaglandin endoperoxide H synthases (cyclooxgenases)-1 and -2. J. Biol. Chem. 271:1996;33157-33160.
3. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell. 87:1996;803-809.
4. Bamba H., Ota S., Kato A., Adachi A., Itoyama S., Matsuzaki F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer. 83:1999;470-475.
5. Marnett L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res. 52:1992;5575-5589.
6. 2 in human colon cancer cells. Cancer Res. 58:1998;362-366.
7. Ota S., Tanaka Y., Bamba H., Kato A., Matsuzaki F. Nonsteroidal anti-inflammatory drugs may prevent colon cancer through suppression of hepatocyte growth factor expression. Eur. J. Pharmacol. 367:1999;131-138.
8. Coleman R. A, Smith W. L., Narumiya S. International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-227.
9. 2 in nuclei. J. Pharmacol. Exp. Ther. 242:1987;306-311.
10. 2 is a ligand for the adipocyte determination factor PPARγ Cell. 83:1995;803-812.
11. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:1995;813-819.
12. Kliewer S. A., Umesono K., Noonan D. J., Heyman R. A., Evans R. M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature. 358:1992;771-774.
13. Palmer C. N. A., Hsu M. H., Griffin K. J., Johnson E. F. Novel sequence determinants in peroxisome proliferator signaling. J. Biol. Chem. 270:1995;16114-16121.
14. Tontonoz P., Hu E., Graves R. A., Budavari A. I., Spiegelman B. M. mPPARγ2: Tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8:1994;1224-1234.
15. Tontnoz P., Nagy L., Alvarez J. G. A., Thomazy V. A., Evans R. M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252.
16. Mueller E., Sarraf P., Tontonoz P., Evans R. M., Martin K. J., Zhang M., Fletcher C., Singer S., Spiegelman B. M. Terminal differentiation of human breast cancer through PPARγ Mol. Cell. 1:1998;465-470.
17. Kubota T., Koshizuka K., Williamsom E. A., Asou H., Said J. W., Holden S., Miyoshi I., Koeffler H. P. Ligand for peroxisome proliferator-activated receptor γ (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58:1998;3344-3352.
18. Dubois R. N., Gupta R., Brockman J., Reddy B. S., Krakow S. L., Lazar M. A. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis. 19:1998;49-53.
19. Min/+ mice. Nature Med. 4:1998;1053-1057.
20. Saez E., Tontonoz P., Nelson M. C., Alvarez J. G. A., U T. M., Baird S. M., Thomazy V. A., Evans R. M. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nature Med. 4:1998;1058-1061.
21. Sarraf P., Mueller E., Jones D., King F. J., DeAngelo D. J., Partridge J. B., Holden S. A., Chen L. B., Singer S., Fletcher C., Sprigelman B. M. Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Med. 4:1998;1046-1052.
22. Hong W. K., Sporn M. B. Recent advances in chemoprevention of cancer. Science. 278:1997;1073-1077.
23. 1 in osteoblasts. J. Clin. Invest. 93:1994;2490-2496.
24. Ben-Av P., Crofford L. J., Wilder R. L., Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: A potential mechanism for inflammatory angiogenesis. FEBS. Lett. 372:1995;83-87.
25. Ferrara N., Leung D. W., Cachianes G., Winer J., Henzel W. J. Purification and cloning of vascular endothelial growth factor secreted by pituitary folliculostellate cells. Methods Enzymol. 198:1991;391-405.
26. Takahashi Y., Kitadai Y., Bucana C. D., Cleary K. R., Ellis L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:1995;3964-3968.
27. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 262:1993;841-844.
28. Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Senger D. R., Dvorak H. F. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53:1993;4727-4735.
29. Harris P., Ralph P. Human leukemic models of myelomonocytic development: A review of the HL-60 and U937 cell lines. J. Leukocyte Biol. 37:1985;407-422.
30. Holness C. L., Simmons D. L. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood. 81:1993;1607-1613.
31. Hoff T., DeWitt D., Kaever V., Resch K., Goppelt-Struebe M. Differentiation-associated expression of prostaglandin G/H synthase in monocytic cells. FEBS. Lett. 320:1993;38-42.
32. 2 by tissue-fixed macrophages in colonic carcinoma. Digestion. 47:1990;160-166.
33. O'Sullivan M. G., Chilton F. H., Huggins E. M., McCall C. E. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J. Biol. Chem. 267:1992;14547-14550.
34. Evans R. Effect of X-irradiation on host-cell infiltration and growth of a murine fibrosarcoma. Br. J. Cancer. 35:1977;557-566.
35. Sunderkötter C., Steinbrink K., Goebeler M., Bhardwaj R., Sorg C. Macrophage and angiogenesis. J. Leukocyte Biol. 55:1994;410-422.
36. 1 and copper in angiogenesis. J. Natl. Cancer Inst. 69:1982;475-482.
37. Connolly D. T., Olander J. V., Heuvelman D., Nelson R., Monsell R., Siegel N., Haymore B. L., Leimgruber R., Feder J. Human vascular permeability factor. Isolation from U937 cells. J. Biol. Chem. 264:1989;20017-20024.
38. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996.
39. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
40. Jiang C., Ting A. T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
41. 2. Distinct roles of cycooxygenase-1 and -2. J. Bio. Chem. 272:1997;25693-25699.